Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon J Harrison

Showing results (61-70 of 153) with videos related to

Pageof 16
Sort By:
Blood|September 5, 2015
Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphomaHeike Richly, Tae Min Kim, Martin Schuler, et al.
Clinical & Translational Immunology|January 13, 2021
Successful identification of predictive profiles for infection utilising systems-level immune analysis: a pilot study in patients with relapsed and refractory multiple myelomaMarcel Doerflinger, Alexandra L Garnham, Saskia Freytag, et al.
British Journal of Haematology|May 11, 2016
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patientsNancy Levin, Andrew Spencer, Simon J Harrison, et al.
Clinical Genitourinary Cancer|November 3, 2024
Chemomobilisation Using Gemcitabine-Oxaliplatin for Salvage High Dose Chemotherapy and Autologous Stem Cell Transplant in Advanced Testicular Germ Cell CancerJane McKenzie, Ciara Conduit, Melissa Ng Liet Hing, et al.
Blood Advances|April 6, 2026
Cytomegalovirus reactivation in multiple myeloma patients receiving bispecific antibodiesEnric Sastre-Escolà, Gemma K Reynolds, Michelle K Yong, et al.
British Journal of Haematology|November 8, 2025
No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases RegistrySueh-Li Lim, Cameron Wellard, Rajeev Rajagopal, et al.
Expert Review of Hematology|December 22, 2021
The development of a home-based therapeutic platform for multiple myelomaHayley Beer, David Routledge, Trish Joyce, et al.
Blood|October 28, 2010
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapyAndy K Hsu, Hang Quach, Tsin Tai, et al.
Haematologica|January 25, 2024
Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapyMika Casey, Carol Lee, Sharon M Hoyte, et al.
Frontiers in Immunology|October 21, 2017
Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune ProfilingBenjamin W Teh, Simon J Harrison, Cody Charles Allison, et al.
Pageof 16

Showing results (61-70 of 153) with videos related to

Sort By:
Pageof 16
Blood|September 5, 2015
Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphomaHeike Richly, Tae Min Kim, Martin Schuler, et al.
Clinical & Translational Immunology|January 13, 2021
Successful identification of predictive profiles for infection utilising systems-level immune analysis: a pilot study in patients with relapsed and refractory multiple myelomaMarcel Doerflinger, Alexandra L Garnham, Saskia Freytag, et al.
British Journal of Haematology|May 11, 2016
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patientsNancy Levin, Andrew Spencer, Simon J Harrison, et al.
Clinical Genitourinary Cancer|November 3, 2024
Chemomobilisation Using Gemcitabine-Oxaliplatin for Salvage High Dose Chemotherapy and Autologous Stem Cell Transplant in Advanced Testicular Germ Cell CancerJane McKenzie, Ciara Conduit, Melissa Ng Liet Hing, et al.
Blood Advances|April 6, 2026
Cytomegalovirus reactivation in multiple myeloma patients receiving bispecific antibodiesEnric Sastre-Escolà, Gemma K Reynolds, Michelle K Yong, et al.
British Journal of Haematology|November 8, 2025
No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases RegistrySueh-Li Lim, Cameron Wellard, Rajeev Rajagopal, et al.
Expert Review of Hematology|December 22, 2021
The development of a home-based therapeutic platform for multiple myelomaHayley Beer, David Routledge, Trish Joyce, et al.
Blood|October 28, 2010
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapyAndy K Hsu, Hang Quach, Tsin Tai, et al.
Haematologica|January 25, 2024
Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapyMika Casey, Carol Lee, Sharon M Hoyte, et al.
Frontiers in Immunology|October 21, 2017
Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune ProfilingBenjamin W Teh, Simon J Harrison, Cody Charles Allison, et al.
Pageof 16